Search
for
Sort by
Research 421–450 of 1000+
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- Dermoscopy of an osteonevus of Nanta
- Endocrinology & Metabolism News, August 2005
- Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
- Extraction and Detection of mRNA from Horsehair
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- Estimation of health utility values for alopecia areata
- The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Filaggrin mutations as an archetype for understanding the pathophysiology of atopic dermatitis
- Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata
- Alopecia Areata Treatment Patterns and Satisfaction: Results of a Real-World Cross-Sectional Survey in Europe
- Prescribing to save patients money: Ethical considerations
- Re: Risk of Erectile Dysfunction Associated with Use of 5α-Reductase Inhibitors for Benign Prostatic Hyperplasia or Alopecia: Population Based Studies Using the Clinical Practice Research Datalink
- Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata
- МИКРОБИОЦЕНОЗ ЛУНОК УДАЛЕННЫХ ЗУБОВ У ПАЦИЕНТОВ С АЛЬВЕОЛИТОМ
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Clinical Manifestation of Alopecia Areata After COVID-19 Infection or Vaccination
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- A clinical study of pemphigus vulgaris and its variants, evaluation of safety and efficacy of glucocorticoids versus immunosuppressants at tertiary care hospital: a study of 75 cases
- Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
- Effects of FGF5-mediated LncRNA on the skin fibroblast growth of Liaoning Cashmere goats
- DETERMINATION OF THE DEGREE OF TISSUE HEATING UNDER THE EXPOSURE TO LASER RADIATION WITH A WAVELENGTH OF 445±40 NM
- Oral Presentations
- Transient perforating folliculitis induced by sorafenib
- Neovascularization during healing of wounds treated with dermal substitutes and fibrin glue in nude mice
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Redox-Responsive Polymer Dot Nanozymes Coordinate Exosome-Mediated Cutaneous Regeneration via Laser-Modulated Microenvironment Remodeling
- Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications